Sickle Cell Disease Treatment Market Share, Size, Growth, Report 2023-2028

Sickle Cell Disease Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Report Format: PDF+Excel | Report ID: SR112023A4076

Year End sale Buy Now

Market Overview:

The global sickle cell disease treatment market size reached US$ 3.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 7.4 Billion by 2028, exhibiting a growth rate (CAGR) of 15.9% during 2023-2028.

Sickle cell disease (SCD) is a genetic red blood cell (RBC) disorder that affects hemoglobin, a protein that carries oxygen throughout the body. It leads to many complications, such as acute chest syndrome, anemia, and vaso-occlusive crisis (VOC). At present, blood and bone marrow transplant is commonly suggested by doctors for treating SCD. It involves replacing affected bone marrow with a healthy substitute received from a donor. Other effective treatments, such as medications and blood transfusions, are also being utilized as they can reduce specific symptoms and prolong the life of patients.

Global Sickle Cell Disease Treatment Market

A considerable increase in the number of individuals suffering from SCD represents one of the significant factors influencing the demand for new medications that can treat the condition effectively. As a result, the health regulatory authorities of numerous countries are focusing on fast-track approval of new treatment methods. For instance, the United States Food and Drug Administration (USFDA) approved a new medicine in 2019 to reduce the pain experienced by adults and children with SCD. Additionally, government authorities are supporting research and development (R&D) activities to encourage researchers and pharmaceutical companies to develop novel treatments. For instance, researchers at the National Heart, Lung, and Blood Institute (NHLBI) in the US are working on genetic therapies that can restore a missing gene or add a new DNA strain to improve the functioning of cells. These innovations, along with the rising disposable incomes and the growing awareness among individuals about the available healthcare services, are anticipated to contribute to market growth.

Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global sickle cell disease treatment market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on treatment type and end user.

Breakup by Treatment Type:

Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

Blood Transfusion
Pharmacotherapy
Bone Marrow Transplant

Breakup by End User:

Hospitals
Diagnostic Centers
Others

Breakup by Region:

To get more information on the regional analysis of this market, Request Sample

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AstraZeneca Plc, Baxter International Inc., bluebird bio Inc., Bristol-Myers Squibb Company, CRISPR Therapeutics, Emmaus Medical Inc., Global Blood Therapeutics Inc., GlycoMimetics Inc., Novartis AG, Pfizer Inc. and Sangamo Therapeutics.

Report Coverage:

Report Features	Details
Base Year of the Analysis	2022
Historical Period	2017-2022
Forecast Period	2023-2028
Units	US$ Billion
Segment Coverage	Treatment Type, End User, Region
Region Covered	Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered	United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered	AstraZeneca Plc, Baxter International Inc., bluebird bio Inc., Bristol-Myers Squibb Company, CRISPR Therapeutics, Emmaus Medical Inc., Global Blood Therapeutics Inc., GlycoMimetics Inc., Novartis AG, Pfizer Inc. and Sangamo Therapeutics
Customization Scope	10% Free Customization
Report Price and Purchase Option	Single User License: US$ 2499 Five User License: US$ 3499 Corporate License: US$ 4499
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report

The global sickle cell disease treatment market was valued at US$ 3.0 Billion in 2022.

We expect the global sickle cell disease treatment market to exhibit a CAGR of 15.9% during 2023-2028.

The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective treatment procedures for sickle cell disease to reduce the risk of the coronavirus infection upon hospital visits and interaction with healthcare professionals or medical equipment.

The rising prevalence of sickle cell disease, along with the growing demand for new medications that can treat the condition effectively, to reduce specific symptoms and prolong the life of patients, is primarily driving the global sickle cell disease treatment market.

Based on the treatment type, the global sickle cell disease treatment market has been segregated into blood transfusion, pharmacotherapy, and bone marrow transplant. Among these, blood transfusion currently holds the largest market share.

Based on the end user, the global sickle cell disease treatment market can be bifurcated into hospitals, diagnostic centers, and others. Currently, hospitals exhibit a clear dominance in the market.

On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Some of the major players in the global sickle cell disease treatment market include AstraZeneca Plc, Baxter International Inc., bluebird bio Inc., Bristol-Myers Squibb Company, CRISPR Therapeutics, Emmaus Medical Inc., Global Blood Therapeutics Inc., GlycoMimetics Inc., Novartis AG, Pfizer Inc., and Sangamo Therapeutics.

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Purchase options Year End sale

Single User License ~~$2499~~ $2249
Five User License ~~$3499~~ $2974
Corporate License ~~$4499~~ $3599

Inquire Before Buying

Speak to an Analyst

Request Brochure

Request Customization

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.